✦ LIBER ✦

A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer

✍ Scribed by Daniel T. Milton; Christopher G. Azzoli; Robert T. Heelan; Ennapadam Venkatraman; Jorge E. Gomez; Mark G. Kris; Lee M. Krug; William Pao; Naiyer A. Rizvi; Megan Dunne; Vincent A. Miller

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 101 KB
Volume: 107
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.22088

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II trial of topotecan and gemcit

A Phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma

✍ David A. Rinaldi; Nancy A. Lormand; Joseph E. Brierre; James L. Cole; Brian C. B 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB 👁 2 views

## Abstract ## BACKGROUND Multiple trials have been performed to evaluate second‐line clinical chemotherapy in patients with advanced nonsmall cell lung carcinoma (NSCLC). However, no single agent or combination has demonstrated superior activity. ## METHODS Patients with advanced NSCLC who had

Randomized phase II study of weekly doce

Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma

✍ Lee M. Krug; Vincent A. Miller; Jyoti Patel; John Crapanzano; Christopher G. Azz 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

A phase II study of weekly docetaxel plu

A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma

✍ Ji-Youn Han; Dae Ho Lee; Hae Young Kim; Eun Kyung Hong; Sung Min Yoon; Jong Ho C 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 2 views

## Abstract ## BACKGROUND Docetaxel is an active agent in advanced nonsmall‐cell lung carcinoma (NSCLC) and demonstrates preclinical and clinical synergism with capecitabine. We conducted the current Phase II study to evaluate the efficacy and safety of the docetaxel/capecitabine combination in ch

Biomarker-based phase I dose-escalation,

Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer

✍ Karen Reckamp; Barbara Gitlitz; Lin-Chi Chen; Ravi Patel; Ginger Milne; Mary Syt 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 1 views

Weekly docetaxel in the treatment of eld

Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma : A Minnie Pearl Cancer Research Network Phase II Trial

✍ John D. Hainsworth; Howard A. Burris III; Sharlene Litchy; Lisa H. Morrissey; Jo 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

## Background: Weekly administration of docetaxel was found to reduce myelosuppression and other nonhematologic toxicities when compared with administration every 3 weeks. in the current phase ii trial, the authors evaluated the feasibility, toxicity, and efficacy of weekly docetaxel in the treatme

Weekly, high-dose paclitaxel in advanced

Weekly, high-dose paclitaxel in advanced lung carcinoma : A Phase II study with pharmacokinetics by the Cancer and Leukemia Group B

✍ Wallace Akerley; James E. Herndon; Merrill J. Egorin; Alan P. Lyss; Hedy L. Kind 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

## Abstract ## BACKGROUND The Cancer and Leukemia Group B conducted a Phase II trial to evaluate the efficacy, toxicity, and pharmacokinetics of paclitaxel administered at a maximum dose density for patients with chemotherapy‐naïve, advanced‐stage non–small cell lung carcinoma (NSCLC). ## METHODS